J Karina Zapata,Javier Gómez-Ambrosi,Gema Frühbeck
J Karina Zapata
Childhood obesity is a global health problem, with its prevalence having tripled since 1975. The increase in its prevalence has been predominantly in developing countries, but also in those with high economic status. Nowadays, there are mul...
Incretins and SGLT-2 inhibitors in diabetic patients with neuroendocrine tumors: current updates and future directions [0.03%]
糖尿病患者的神经内分泌肿瘤的肠降糖激素和SGLT-2抑制剂：当前更新及未来方向
Rosaria M Ruggeri,Erika Maria Grossrubatscher,Eleonora Ciocca et al.
Rosaria M Ruggeri et al.
Neuroendocrine tumors (NET) are frequently associated with glycemic disorders, such as prediabetes or diabetes, which may result from either surgical or medical treatments or hormonal hypersecretion by the tumor itself. Moreover, pre-existi...
Ectopic GHRH production: revisiting a rare cause of acromegaly [0.03%]
异位生长激素释放激素的产生：重新审视一种罕见的肢端肥大症病因
Matheo A M Stumpf,Nathalie Oliveira Santana,Marcio Carlos Machado et al.
Matheo A M Stumpf et al.
Growth Hormone-Releasing Hormone (GHRH) is a hypothalamic hormone that stimulates GH secretion by the anterior pituitary gland. Ectopic production of GHRH by neuroendocrine tumors (NETs) is a rare cause of acromegaly, with some clinical and...
Insulin icodec: A novel once-weekly formulation for the treatment of type 1 and type 2 diabetes mellitus [0.03%]
icodec 胰岛素：一种新型一周一次的配方，用于治疗1型和2型糖尿病
David Q Pham,John Andraos,Joelle Ayoub
David Q Pham
Insulin icodec is a novel once-weekly basal insulin analog subcutaneous injection seeking approval by the United States Food and Drug Administration (FDA) for use in both type 1 and type 2 diabetes mellitus. The mission of this manuscript i...
Riccarda Granata
Riccarda Granata
Cancer screening in patients with acromegaly: a plea for a personalized approach and international registries [0.03%]
肢端肥大症患者的癌症筛查：对个性化方法和国际登记处的呼吁
Luigi Demarchis,Sabrina Chiloiro,Antonella Giampietro et al.
Luigi Demarchis et al.
Acromegaly is a rare condition, and often diagnosis is delayed by several years, for most patients. Acromegaly is characterized by short and long-term respiratory, cardiovascular and metabolic comorbidities, with possible impact on mortalit...
Carlos Dieguez,Miguel López,Felipe Casanueva
Carlos Dieguez
Published Erratum
Reviews in endocrine & metabolic disorders. 2025 Mar 15. DOI:10.1007/s11154-025-09955-8 2025
Skeletal muscle atrophy and dysfunction in obesity and type-2 diabetes mellitus: Myocellular mechanisms involved [0.03%]
肥胖和二型糖尿病中的骨骼肌萎缩与功能障碍：所涉及的肌细胞机制
Íñigo M Pérez Castillo,Josep M Argilés,Ricardo Rueda et al.
Íñigo M Pérez Castillo et al.
Obesity and type-2 diabetes mellitus (T2DM) are interrelated metabolic disorders primarily driven by overnutrition and physical inactivity, which oftentimes entails a transition from obesity to T2DM. Compromised musculoskeletal health consi...
Melatonin administration on bone properties of animals under hypoestrogenism: A systematic review [0.03%]
低雌激素状态下褪黑素对动物骨特性影响的系统评价
Taciane Maria Melges Pejon,Leonardo Henrique Dalcheco Messias,Rafael Henrique de Oliveira Nascimento et al.
Taciane Maria Melges Pejon et al.
Purpose: Hypoestrogenism is associated with loss of bone mass and strength. Melatonin has become a strategy due to its actions on bone tissue. This review summarizes the available data on the effects of chronic melatonin ...
Are strategies to increase muscle mass and strength as effective in people with type 2 diabetes? [0.03%]
增加肌肉质量和力量的策略对二型糖尿病患者是否同样有效？
Amina A Al-Awadi,Stuart R Gray,Ebaa Al-Ozairi
Amina A Al-Awadi
People with type 2 diabetes (T2D) have a 2-3-time higher risk of developing sarcopenia, a musculoskeletal disease marked by a progressive loss of skeletal muscle mass and strength, compared to people without T2D. This narrative review exami...